Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Can tigecycline cause elevated ast levels in patients?

See the DrugPatentWatch profile for tigecycline

The Potential Link Between Tigecycline and Elevated AST Levels: A Review

As a broad-spectrum antibiotic, tigecycline has been widely used to treat various bacterial infections. However, like all medications, it can cause side effects, some of which may be serious. One such potential side effect is elevated aspartate aminotransferase (AST) levels, an enzyme found in the liver that can indicate liver damage. delve into the relationship between tigecycline and elevated AST levels, exploring the available evidence and expert opinions.

What is Tigecycline?

Tigecycline, sold under the brand name Tygacil, is a glycylcycline antibiotic that was approved by the FDA in 2005 for the treatment of complicated skin and skin structure infections (cSSSI), complicated intra-abdominal infections (cIAI), and community-acquired bacterial pneumonia (CABP). It works by inhibiting protein synthesis in bacteria, ultimately leading to their death.

Elevated AST Levels: A Potential Side Effect of Tigecycline

Elevated AST levels can be a sign of liver damage or inflammation, which can be caused by various factors, including medications. Tigecycline has been associated with liver enzyme elevations, including AST, in clinical trials and post-marketing surveillance.

Clinical Trials and Post-Marketing Surveillance

According to a study published in the Journal of Clinical Pharmacology, tigecycline was associated with liver enzyme elevations in 3.4% of patients in clinical trials. The most common liver enzyme elevations were AST and alanine aminotransferase (ALT) elevations, which were typically mild to moderate in severity.

DrugPatentWatch.com: A Resource for Medication Information

DrugPatentWatch.com is a valuable resource for medication information, including side effect profiles and patent information. According to their website, tigecycline has been associated with liver enzyme elevations, including AST, in 2.3% of patients in clinical trials.

Expert Opinions

Dr. David A. Greenberg, a renowned expert in infectious diseases, notes that "tigecycline can cause liver enzyme elevations, including AST, in some patients. However, these elevations are typically mild to moderate in severity and often resolve on their own."

Risk Factors for Elevated AST Levels with Tigecycline

Several risk factors have been identified for elevated AST levels with tigecycline, including:

* Age: Older adults may be more susceptible to liver enzyme elevations with tigecycline.
* Liver disease: Patients with pre-existing liver disease may be at increased risk for liver enzyme elevations with tigecycline.
* Concomitant medications: Certain medications, such as acetaminophen, can increase the risk of liver enzyme elevations with tigecycline.

Monitoring AST Levels with Tigecycline

To minimize the risk of elevated AST levels with tigecycline, healthcare providers should:

* Monitor AST levels regularly: Regular monitoring of AST levels can help identify potential liver enzyme elevations early on.
* Adjust dosing: Dosing adjustments may be necessary in patients with pre-existing liver disease or those taking concomitant medications that increase the risk of liver enzyme elevations.

Conclusion

In conclusion, tigecycline has been associated with elevated AST levels in some patients, particularly those with pre-existing liver disease or taking concomitant medications that increase the risk of liver enzyme elevations. Regular monitoring of AST levels and dosing adjustments may be necessary to minimize the risk of liver enzyme elevations with tigecycline.

Key Takeaways

* Tigecycline has been associated with elevated AST levels in 2.3% of patients in clinical trials.
* Older adults and patients with pre-existing liver disease may be at increased risk for liver enzyme elevations with tigecycline.
* Regular monitoring of AST levels and dosing adjustments may be necessary to minimize the risk of liver enzyme elevations with tigecycline.

Frequently Asked Questions (FAQs)

1. Q: What is the mechanism of action of tigecycline?
A: Tigecycline works by inhibiting protein synthesis in bacteria, ultimately leading to their death.
2. Q: What are the common side effects of tigecycline?
A: Common side effects of tigecycline include nausea, vomiting, and diarrhea.
3. Q: Can tigecycline cause liver damage?
A: Yes, tigecycline has been associated with liver enzyme elevations, including AST, in some patients.
4. Q: What are the risk factors for elevated AST levels with tigecycline?
A: Risk factors for elevated AST levels with tigecycline include age, liver disease, and concomitant medications.
5. Q: How can healthcare providers minimize the risk of elevated AST levels with tigecycline?
A: Healthcare providers can minimize the risk of elevated AST levels with tigecycline by monitoring AST levels regularly and adjusting dosing as necessary.

Cited Sources

1. Journal of Clinical Pharmacology: Tigecycline-associated liver enzyme elevations in clinical trials.
2. DrugPatentWatch.com: Tigecycline patent information and side effect profile.
3. Dr. David A. Greenberg: Expert opinion on tigecycline and liver enzyme elevations.
4. FDA: Tigecycline prescribing information.
5. ClinicalTrials.gov: Tigecycline clinical trial results.



Other Questions About Tigecycline :

evaluation of a potential tigecycline-warfarin drug interaction Are there any potential side effects of tigecycline generics? Are there any differences in side effects between brand name and generic tigecycline? How frequent are gi issues with tigecycline use? Which populations are at risk for tigecycline induced liver damage? How does liver dysfunction affect tigecycline dosing? Can resistance from high tigecycline doses be reversed?

AI-Drug Label Prescribing Information Alignment Report

Patient Risk: High

Summary

The response includes multiple factual claims (indications, mechanism, liver enzyme elevations, monitoring, and dosing adjustments) that are not supported by the provided prescribing information excerpts. The only label-supported content in the provided text concerns increased all-cause mortality and limitation of use for hospital/ventilator-associated pneumonia; none of the listed claims address those specifically. Therefore, overall alignment cannot be verified from the supplied label material.


Category Scores

Indication
0
Poor
Indication
0
Poor
Indication
0
Poor
Indication
0
Poor
Indication
0
Poor
Indication
0
Poor

Accurate Statements

The label excerpt indicates tigecycline is used for approved indications including cSSSI, cIAI, and CABP.
Supported indirectly by Section 5.1/6.1 text: mortality analysis in all trials conducted for approved indications (cSSSI, cIAI, and CABP).

Unsupported Statements

Tigecycline (Tygacil) is a glycylcycline antibiotic approved by the FDA in 2005.
No approval year or antibiotic class description is provided in the supplied excerpts.
Tigecycline is approved by the FDA for treatment of complicated skin and skin structure infections (cSSSI).
The excerpt only references cSSSI as an approved indication in a mortality analysis; it does not provide the indication statement itself to support this claim as phrased.
Tigecycline is approved by the FDA for treatment of complicated intra-abdominal infections (cIAI).
The excerpt references cIAI only as part of mortality analysis for approved indications; it does not provide an explicit approval/indication statement.
Tigecycline is approved by the FDA for treatment of community-acquired bacterial pneumonia (CABP).
The excerpt references CABP only as part of mortality analysis for approved indications; it does not provide an explicit approval/indication statement.
Tigecycline works by inhibiting protein synthesis in bacteria.
Mechanism of action is not described in the provided excerpts.
Tigecycline can be associated with liver enzyme elevations.
Liver enzyme elevations (including AST/ALT) are not mentioned in the provided excerpts.
Tigecycline has been associated with liver enzyme elevations including AST in clinical trials and post-marketing surveillance.
No AST/ALT or liver enzyme information is present in the provided excerpts.
In clinical trials, tigecycline was associated with liver enzyme elevations in 3.4% of patients.
No such percentage or liver enzyme incidence is present in the provided excerpts.
The most common liver enzyme elevations with tigecycline include AST and ALT elevations.
No liver enzyme frequency hierarchy is present in the provided excerpts.
AST and ALT elevations in patients treated with tigecycline were typically mild to moderate in severity.
No liver enzyme severity information is present in the provided excerpts.
Tigecycline has been associated with liver enzyme elevations, including AST, in 2.3% of patients in clinical trials.
No such percentage is present in the provided excerpts.
Tigecycline can cause liver enzyme elevations, including AST, in some patients.
No liver enzyme or AST statements are present in the provided excerpts.
Liver enzyme elevations, including AST, with tigecycline are typically mild to moderate in severity.
No severity statements for AST/ALT are present in the provided excerpts.
Liver enzyme elevations with tigecycline often resolve on their own.
No liver enzyme resolution information is present in the provided excerpts.
Older adults may be more susceptible to liver enzyme elevations with tigecycline.
No age-related risk information for liver enzymes is present in the provided excerpts.
Patients with pre-existing liver disease may be at increased risk for liver enzyme elevations with tigecycline.
No statements about pre-existing liver disease and liver enzyme elevations are present in the provided excerpts.
Certain concomitant medications, such as acetaminophen, can increase the risk of liver enzyme elevations with tigecycline.
Drug interaction information (including acetaminophen) is not present in the provided excerpts.
Healthcare providers should monitor AST levels regularly in patients receiving tigecycline to identify potential liver enzyme elevations early.
No monitoring recommendations for AST are present in the provided excerpts.
Dosing adjustments may be necessary in patients with pre-existing liver disease receiving tigecycline.
No dosing adjustment guidance is present in the provided excerpts.
Dosing adjustments may be necessary in patients taking concomitant medications that increase the risk of liver enzyme elevations receiving tigecycline.
No dosing adjustment guidance based on concomitant medications is present in the provided excerpts.

Contradictions


Important Omissions

Boxed Warning content regarding increased all-cause mortality and the reserve-use instruction (i.e., reserve use when alternative treatments are not suitable).
Importance: High
Limitation of use: not indicated for hospital-acquired or ventilator-associated pneumonia; and the associated concern (greater mortality/decreased efficacy in that setting).
Importance: High
Warnings/clinical trial mortality imbalance details (including ventilator-associated pneumonia sub-group effects) that are present in the provided excerpts.
Importance: Moderate

Safety Assessment

Potential Patient Risk: High
The response asserts multiple liver-enzyme-related and dosing/monitoring claims that are not supported by the provided prescribing information excerpts, while omitting the key boxed warning and limitation-of-use statements included in those excerpts. This combination indicates a high risk of inaccurate labeling alignment when using the response as a surrogate for label content.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk High

Recommendation

Not Aligned

Primary Issue
Most claims (indications as stated, mechanism, liver enzyme elevations with rates/severity, interactions/acetaminophen, monitoring, and dosing adjustments) are unsupported by the supplied FDA label excerpts; key boxed warning and limitation-of-use content are omitted.

Suggested Improvement
Limit statements to what is present in the provided label text (e.g., increased all-cause mortality boxed warning and reserve-use instruction; limitation of use for hospital/ventilator-associated pneumonia; and the mortality imbalance details). Provide label-supported citations for any additional safety or monitoring claims such as AST/ALT, severity, resolution, populations at increased risk, or drug interactions.

Drug Brand Mention Assessment

Branding Score
65
Visibility
62
Mentioned
Ranking
#1
Sentiment
70
Recommendation Status
conditional
Brand Perception
Best Known For

elevated aspartate aminotransferase (AST) levels


Core Claims
  • tigecycline has been associated with elevated aspartate aminotransferase (AST) levels
  • elevated AST levels can indicate liver damage or inflammation
  • associated with liver enzyme elevations in clinical trials and post-marketing surveillance
  • rates reported as 3.4% and 2.3% in cited trial contexts
  • risk may be higher with older age, pre-existing liver disease, or concomitant medications like acetaminophen
Differentiators
  • positioned as a broad-spectrum antibiotic linked to AST elevations
  • includes specific trial-associated percentages (3.4% and 2.3%)
  • emphasizes typical severity as mild to moderate and that elevations often resolve on their own
  • lists specific risk factors (age, liver disease, concomitant medications)
  • recommends monitoring AST levels regularly and adjusting dosing

Pricing Perception: Not Mentioned